Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2016; 22(20): 4812-4823
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4812
Current and emerging therapies in unresectable and recurrent gastric cancer
Erin Jou, Lakshmi Rajdev
Erin Jou, Lakshmi Rajdev, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, United States
Author contributions: Jou E and Rajdev L contributed equally to this work.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Lakshmi Rajdev, MD, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10467, United States.
Telephone: +1-718-4058404 Fax: +1-718-4058433
Received: February 25, 2016
Peer-review started: February 25, 2016
First decision: March 31, 2016
Revised: April 8, 2016
Accepted: April 20, 2016
Article in press: April 20, 2016
Published online: May 28, 2016
Core Tip

Core tip: Despite many advances in medical and surgical treatments, gastric cancer remains the second leading cause of cancer deaths. There is a greater understanding of the molecular heterogeneity of gastric cancer in recent years, resulting in the development and clinical investigation of different targeted agents. This review will discuss current treatment strategies and highlight targeted therapies and emerging drugs for advanced gastric cancer.